{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.0"},{"groupId":"OG001","spread":"9.16","value":"19.4"},{"groupId":"OG002","spread":"7.28","value":"10.0"},{"groupId":"OG003","spread":"14.2","value":"24.3"},{"groupId":"OG004","spread":"6.06","value":"6.8"},{"groupId":"OG005","spread":"14.8","value":"26.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"25"}],"units":"Participants"}],"description":"Blood samples were collected during the Randomization Phase. Most participants had 6 samples taken over 3 cycles of treatment (sparse sampling - 2 samples taken per cycle, one at predose and one at 2 to 8 hours postdose). Whole blood concentrations of everolimus were measured and concentration data were summarized. The summary statistics at time points with one or more BLQ values were calculated by assigning zero for each BLQ value.","dispersionType":"Standard Deviation","groups":[{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected immediately prior to study drug administration.","id":"OG000","title":"Cycle 1, Day 1 (0 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected 2 to 8 hours after study drug administration.","id":"OG001","title":"Cycle 1, Day 1 (2-8 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected immediately prior to study drug administration.","id":"OG002","title":"Cycle 2, Day 1 (0 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected 2 to 8 hours after study drug administration.","id":"OG003","title":"Cycle 2, Day 1 (2-8 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected immediately prior to study drug administration.","id":"OG004","title":"Cycle 3, Day 1 (0 Hours)"},{"description":"Lenvatinib (18 mg) and everolimus (5 mg) were administered as described previously. Blood samples were collected 2 to 8 hours after study drug administration.","id":"OG005","title":"Cycle 3, Day 1 (2-8 Hours)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set included all participants who received at least one dose of study drug (lenvatinib or everolimus) and had evaluable concentration data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Day 1), Cycle 2 (Day 1), Cycle 3 (Day 1)","title":"Summary of Blood Concentrations of Everolimus for Sparse PK Sampling for Phase 1b and Phase 2","type":"SECONDARY","unitOfMeasure":"ng/mL"}